000155720 001__ 155720
000155720 005__ 20240302115203.0
000155720 0247_ $$2doi$$a10.1016/j.neurobiolaging.2021.02.024
000155720 0247_ $$2pmid$$apmid:33896652
000155720 0247_ $$2ISSN$$a0197-4580
000155720 0247_ $$2ISSN$$a1558-1497
000155720 0247_ $$2altmetric$$aaltmetric:104732193
000155720 037__ $$aDZNE-2021-00888
000155720 041__ $$aEnglish
000155720 082__ $$a610
000155720 1001_ $$avan der Ende, Emma L$$b0
000155720 245__ $$aCSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia.
000155720 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2021
000155720 3367_ $$2DRIVER$$aarticle
000155720 3367_ $$2DataCite$$aOutput Types/Journal article
000155720 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1709305874_5354
000155720 3367_ $$2BibTeX$$aARTICLE
000155720 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155720 3367_ $$00$$2EndNote$$aJournal Article
000155720 520__ $$aExcessive microglial activation might be a central pathological process in GRN-related frontotemporal dementia (FTD-GRN). We measured soluble triggering receptor expressed on myeloid cells 2 (sTREM2), which is shed from disease-associated microglia following cleavage of TREM2, in cerebrospinal fluid of 34 presymptomatic and 35 symptomatic GRN mutation carriers, 6 presymptomatic and 32 symptomatic C9orf72 mutation carriers and 67 healthy noncarriers by ELISA. Although no group differences in sTREM2 levels were observed (GRN: symptomatic (median 5.2 ng/mL, interquartile range [3.9-9.2]) vs. presymptomatic (4.3 ng/mL [2.6-6.1]) vs. noncarriers (4.2 ng/mL [2.6-5.5]): p = 0.059; C9orf72: symptomatic (4.3 [2.9-7.0]) vs. presymptomatic (3.2 [2.2-4.2]) vs. noncarriers: p = 0.294), high levels were seen in a subset of GRN, but not C9orf72, mutation carriers, which might reflect differential TREM2-related microglial activation. Interestingly, 2 presymptomatic carriers with low sTREM2 levels developed symptoms after 1 year, whereas 2 with high levels became symptomatic after >5 years. While sTREM2 is not a promising diagnostic biomarker for FTD-GRN or FTD-C9orf72, further research might elucidate its potential to monitor microglial activity and predict disease progression.
000155720 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000155720 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000155720 650_7 $$2Other$$aBiomarker
000155720 650_7 $$2Other$$aCerebrospinal fluid
000155720 650_7 $$2Other$$aFrontotemporal dementia
000155720 650_7 $$2Other$$aMicroglia
000155720 650_7 $$2Other$$asTREM2
000155720 650_2 $$2MeSH$$aAdult
000155720 650_2 $$2MeSH$$aAged
000155720 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000155720 650_2 $$2MeSH$$aC9orf72 Protein: genetics
000155720 650_2 $$2MeSH$$aFemale
000155720 650_2 $$2MeSH$$aFrontotemporal Dementia: diagnosis
000155720 650_2 $$2MeSH$$aFrontotemporal Dementia: genetics
000155720 650_2 $$2MeSH$$aHeterozygote
000155720 650_2 $$2MeSH$$aHumans
000155720 650_2 $$2MeSH$$aMale
000155720 650_2 $$2MeSH$$aMembrane Glycoproteins: cerebrospinal fluid
000155720 650_2 $$2MeSH$$aMembrane Glycoproteins: metabolism
000155720 650_2 $$2MeSH$$aMicroglia: metabolism
000155720 650_2 $$2MeSH$$aMicroglia: physiology
000155720 650_2 $$2MeSH$$aMiddle Aged
000155720 650_2 $$2MeSH$$aMutation
000155720 650_2 $$2MeSH$$aProgranulins: genetics
000155720 650_2 $$2MeSH$$aReceptors, Immunologic: metabolism
000155720 7001_ $$0P:(DE-2719)2812759$$aMorenas-Rodriguez, Estrella$$b1$$udzne
000155720 7001_ $$aMcMillan, Corey$$b2
000155720 7001_ $$aGrossman, Murray$$b3
000155720 7001_ $$aIrwin, David$$b4
000155720 7001_ $$aSanchez-Valle, Raquel$$b5
000155720 7001_ $$aGraff, Caroline$$b6
000155720 7001_ $$aVandenberghe, Rik$$b7
000155720 7001_ $$aPijnenburg, Yolande A L$$b8
000155720 7001_ $$aLaforce, Robert$$b9
000155720 7001_ $$aBer, Isabelle Le$$b10
000155720 7001_ $$aLleo, Alberto$$b11
000155720 7001_ $$0P:(DE-2719)2202037$$aHaass, Christian$$b12$$udzne
000155720 7001_ $$0P:(DE-2719)2811727$$aSuarez-Calvet, Marc$$b13$$udzne
000155720 7001_ $$avan Swieten, John C$$b14
000155720 7001_ $$aSeelaar, Harro$$b15
000155720 773__ $$0PERI:(DE-600)1498414-3$$a10.1016/j.neurobiolaging.2021.02.024$$gVol. 103, p. 158.e1 - 158.e5$$p158.e1 - 158.e5$$tNeurobiology of aging$$v103$$x0197-4580$$y2021
000155720 8564_ $$uhttps://pub.dzne.de/record/155720/files/DZNE-2021-00888.pdf$$yOpenAccess
000155720 8564_ $$uhttps://pub.dzne.de/record/155720/files/DZNE-2021-00888.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000155720 909CO $$ooai:pub.dzne.de:155720$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000155720 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812759$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000155720 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2202037$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000155720 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811727$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000155720 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000155720 9141_ $$y2021
000155720 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000155720 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000155720 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000155720 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000155720 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000155720 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-10$$wger
000155720 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROBIOL AGING : 2021$$d2022-11-10
000155720 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-10
000155720 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-10
000155720 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-10
000155720 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-10
000155720 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-10
000155720 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-10
000155720 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-10
000155720 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-10
000155720 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROBIOL AGING : 2021$$d2022-11-10
000155720 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000155720 980__ $$ajournal
000155720 980__ $$aVDB
000155720 980__ $$aI:(DE-2719)1110007
000155720 980__ $$aUNRESTRICTED
000155720 9801_ $$aFullTexts